| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 11,771.67 | 11,055.93 | 11,025.66 | 10,080.58 |
yoy growth (%) | 6.47 | 0.27 | 9.37 | -20.16 |
Raw materials | -4,467.26 | -4,182.31 | -4,207.27 | -3,474.35 |
As % of sales | 37.94 | 37.82 | 38.15 | 34.46 |
Employee costs | -1,918.16 | -1,695.86 | -1,703.22 | -1,441.64 |
As % of sales | 16.29 | 15.33 | 15.44 | 14.3 |
Other costs | -5,177.11 | -3,133.7 | -3,207.56 | -3,078.73 |
As % of sales (Other Cost) | 43.97 | 28.34 | 29.09 | 30.54 |
Operating profit | 209.14 | 2,044.06 | 1,907.61 | 2,085.86 |
OPM | 1.77 | 18.48 | 17.3 | 20.69 |
Depreciation | -514.19 | -502.83 | -518.75 | -389.81 |
Interest expense | -73.47 | -40.62 | -52.59 | -33.24 |
Other income | 216.99 | 129.09 | 475.19 | 131.12 |
Profit before tax | -161.53 | 1,629.7 | 1,811.46 | 1,793.93 |
Taxes | -27.17 | -371.08 | -324.7 | -449.27 |
Tax rate | 16.82 | -22.76 | -17.92 | -25.04 |
Minorities and other | 0 | 0 | 0 | 0 |
Adj. profit | -188.7 | 1,258.62 | 1,486.76 | 1,344.66 |
Exceptional items | 0 | 0 | -759.21 | 0 |
Net profit | -188.7 | 1,258.62 | 727.55 | 1,344.66 |
yoy growth (%) | -114.99 | 72.99 | -45.89 | -57.19 |
NPM | -1.6 | 11.38 | 6.59 | 13.33 |
This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.
Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.
The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.
The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.
StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.
Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.
The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.
The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.
The acquisition enhances Lupin’s portfolio of branded medicines and is aimed at furthering the company’s commitment to providing affordable and sustainable healthcare solutions.
Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
